drugset / Trial / NCT00468312

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)

NCT00468312

Phase 3 Completed 429 enrolled Organon and Co
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to assess the effectiveness of mometasone furoate nasal spray (MFNS) once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total symptom score.

Timeline

Start
2007-03
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mometasone furoate Other / unclassified 200 ug Intranasal